NO991424D0 - Anvendelse av sibutraminanaloger for Õ senke lipidnivÕer - Google Patents

Anvendelse av sibutraminanaloger for Õ senke lipidnivÕer

Info

Publication number
NO991424D0
NO991424D0 NO991424A NO991424A NO991424D0 NO 991424 D0 NO991424 D0 NO 991424D0 NO 991424 A NO991424 A NO 991424A NO 991424 A NO991424 A NO 991424A NO 991424 D0 NO991424 D0 NO 991424D0
Authority
NO
Norway
Prior art keywords
lipid levels
lowering lipid
humans
sibutramine
analogues
Prior art date
Application number
NO991424A
Other languages
English (en)
Norwegian (no)
Other versions
NO991424L (no
Inventor
Peter Finian Kelly
Stephen Paul Jones
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of NO991424L publication Critical patent/NO991424L/no
Publication of NO991424D0 publication Critical patent/NO991424D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fats And Perfumes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Analogue/Digital Conversion (AREA)
NO991424A 1996-09-25 1999-03-24 Anvendelse av sibutraminanaloger for Õ senke lipidnivÕer NO991424D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619961.7A GB9619961D0 (en) 1996-09-25 1996-09-25 Medical treatment
PCT/EP1997/005040 WO1998013034A1 (en) 1996-09-25 1997-09-15 Use of sibutramine analogues to lower lipid levels

Publications (2)

Publication Number Publication Date
NO991424L NO991424L (no) 1999-03-24
NO991424D0 true NO991424D0 (no) 1999-03-24

Family

ID=10800447

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991424A NO991424D0 (no) 1996-09-25 1999-03-24 Anvendelse av sibutraminanaloger for Õ senke lipidnivÕer

Country Status (26)

Country Link
US (1) US6187820B1 (https=)
EP (1) EP0973511B1 (https=)
JP (1) JP4143126B2 (https=)
KR (1) KR100573333B1 (https=)
CN (1) CN1173696C (https=)
AT (1) ATE239459T1 (https=)
AU (1) AU724645B2 (https=)
BG (1) BG64472B1 (https=)
BR (1) BR9711411A (https=)
CA (1) CA2266378C (https=)
CZ (1) CZ291879B6 (https=)
DE (1) DE69721833T2 (https=)
DK (1) DK0973511T3 (https=)
ES (1) ES2199354T3 (https=)
GB (1) GB9619961D0 (https=)
HU (1) HU224711B1 (https=)
IL (1) IL128820A (https=)
NO (1) NO991424D0 (https=)
NZ (1) NZ334550A (https=)
PL (1) PL190017B1 (https=)
PT (1) PT973511E (https=)
RU (1) RU2197959C2 (https=)
SK (1) SK284282B6 (https=)
TR (1) TR199900648T2 (https=)
UA (1) UA63916C2 (https=)
WO (1) WO1998013034A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
AU3894500A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
JP4278652B2 (ja) * 2002-10-05 2009-06-17 ハンミ ファーム． シーオー．， エルティーディー． 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
EP1622600A1 (en) * 2003-04-28 2006-02-08 Cipla Ltd. Pharmaceutical formulation comprising anti-obesity agent and acidulant
US20050032908A1 (en) * 2003-08-04 2005-02-10 Beckman Kristen M. Methods for treating metabolic syndrome
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
KR100618176B1 (ko) 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
KR20060080817A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
WO2006073292A1 (en) * 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR100814384B1 (ko) * 2006-02-10 2008-03-18 대화제약 주식회사 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법
WO2008034142A2 (en) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
WO2010082216A2 (en) * 2008-12-08 2010-07-22 Matrix Laboratories Ltd Novel salts of sibutramine and their crystal forms
RU2642074C2 (ru) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
SK284282B6 (sk) 2004-12-01
JP4143126B2 (ja) 2008-09-03
KR20000048567A (ko) 2000-07-25
CA2266378A1 (en) 1998-04-02
IL128820A (en) 2001-10-31
DE69721833D1 (de) 2003-06-12
BR9711411A (pt) 1999-08-17
BG64472B1 (bg) 2005-04-30
NO991424L (no) 1999-03-24
JP2001500883A (ja) 2001-01-23
US6187820B1 (en) 2001-02-13
HU224711B1 (en) 2006-01-30
CA2266378C (en) 2007-02-13
DK0973511T3 (da) 2003-08-25
EP0973511A1 (en) 2000-01-26
HUP9903823A3 (en) 2000-07-28
BG103249A (bg) 1999-09-30
KR100573333B1 (ko) 2006-04-24
UA63916C2 (uk) 2004-02-16
RU2197959C2 (ru) 2003-02-10
AU724645B2 (en) 2000-09-28
CZ291879B6 (cs) 2003-06-18
ATE239459T1 (de) 2003-05-15
PT973511E (pt) 2003-08-29
PL332367A1 (en) 1999-09-13
AU4774197A (en) 1998-04-17
SK32099A3 (en) 1999-12-10
EP0973511B1 (en) 2003-05-07
WO1998013034A1 (en) 1998-04-02
NZ334550A (en) 2000-09-29
GB9619961D0 (en) 1996-11-13
IL128820A0 (en) 2000-01-31
CN1231605A (zh) 1999-10-13
HUP9903823A2 (hu) 2000-06-28
CN1173696C (zh) 2004-11-03
ES2199354T3 (es) 2004-02-16
CZ93299A3 (cs) 2000-07-12
TR199900648T2 (xx) 1999-06-21
PL190017B1 (pl) 2005-10-31
DE69721833T2 (de) 2003-12-24

Similar Documents

Publication Publication Date Title
NO991424D0 (no) Anvendelse av sibutraminanaloger for Õ senke lipidnivÕer
ATE232720T1 (de) Adjuvans für impfstoff
ES2166817T3 (es) Mejora de la tolerancia a la glucosa.
WO2002000209A3 (en) Gabapentin analogues for sleep disorders
MY117971A (en) Denaturants for sympathomimetic amine salts
HUP0004287A2 (hu) Venlafaxin-hidrokloridot tartalmazó nyújtott hatóanyagleadású készítmény
BR0311193A (pt) Aduto de topiramato e cloridrato de tramadol e usos dos mesmos
ATE239460T1 (de) 1-(1-(4-chlorphenyl)cyclobutyl)-3-methylbutyl amin derivate zur senkung von harnsäurespiegeln beim menschen
CA2264528A1 (en) Fungicidal mixtures
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
DK1169029T3 (da) Anvendelse af sibutramin eller et derivat deraf til behandling af sövnforstyrrelser
BR0112600A (pt) Compostos calcilìticos
SE9603285D0 (sv) New compounds
BR0210539A (pt) Processos de seleção e uso de vacinas de vetor antiartrópode
EE200200583A (et) (E)-N-(6,6-dimetüül-2-hepteen-4-ünüül)-N-metüül-1-naftaleenmetaanamiini (terbinafiin) valmistamise meetod
ATE282608T1 (de) Chinoxalindionen
HK1045254A1 (zh) 降低血小板黏性的处理方法
UY28111A1 (es) Nueva forma de dosificación oral de liberación inmediata
RU99126233A (ru) Антиаритмическое средство
BG105999A (en) Treatment of osteoarthritis
WO2003058670A3 (en) A crt having a shadow mask vibration damper
MXPA01009468A (es) Tratamiento de hipertension pulmonar.
MXPA01009465A (es) Perdida de peso despues del embarazo.
TR200200949T2 (tr) Polimorfik N-[3-[[2-(3,4-dimetoksifenil)etil]amino]propil]-4-nitro benzamid hidroklorid
BG106000A (en) Treatment of hiatial hernia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application